A lady is taking Novo Nordisk to court docket over what she claims had been unfavourable unwanted side effects she skilled after utilizing Ozempic โฆ alleging the corporate knew it may jack up your intestine.
Caren Elosua simply filed go well with in opposition to the pharmaceutical large, claiming weight reduction meds like Ozempic and Wegovy have lengthy been suspected of being able to inflicting critical hurt primarily based on research and trials โฆ particularly in an individualโs abdomen and gastrointestinal system.
In her docs, obtained by TMZ, Elosua says that even with this alleged historical past of unwanted side effects in thoughts โฆ she was nonetheless prescribed Ozempic to fight her type-2 diabetes.
Elosua says she began taking a dose of 1ml of Ozempic injections weekly beginning in April 2021, and goes on to say her dosage was elevated by her doc to 2ml a pair years later.
However, towards the tip of 2023 โฆ Elosua claims she began to endure from signs like complications, vomiting, cramping and extreme abdomen ache โ so she says she went to see a specialist โฆ who she says did a abdomen emptying take a look at on her to see what was up.
As it seems, she claims this gastroenterologist recognized her with gastroparesis โ which suggests your abdomen muscle groups get tremendous weak and are not in a position to correctly digest meals โ and he or she alleges {that a} second physician confirmed this prognosis.
She says her final Ozempic shot was round late January โ however by then, she claims the harm had been completed โฆ alleging she needed to be hospitalized because of the fixed ache she was experiencing, which she claims has severely torn up her stomach space.
Elosua claims Novo Nordisk โ the corporate behind Ozempic โ knew this miracle drug may screw individuals up inside, however they cranked it out anyway and made a fortune โฆ along with her claiming it got here on the well being expense of her and probably others.
Now, sheโs in search of main damages. We reached out to Novo Nordisk โฆ no phrase again but.
Discussion about this post